5-2,-06

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number.

## **Application Number** 10/751543-Conf. #2403 Filing Date **TRANSMITTAL** January 5, 2004 **FORM** First Named Inventor M. Merle ELLOSO Art Unit 1617 (to be used for all correspondence after initial filing) **Examiner Name** S. Kantamneni

Attorney Docket Number

Total Number of Pages in This Submission		3	Attorney Docket Number		0036119.00161US2/AM101281		
ENCLOSURES (Check all that apply)							
Fee Transmittal Form		Drawing(s)			After Allowance Communication to TC		
Fee Attached		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences		
Amendment/Reply		Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final		Petition to Co Provisional A			Proprietary Information		
Affidavits/declaration(s)		Power of Attor Change of Co	ney, Revocation rrespondence A	n .ddress	Status Letter		
Extension of Time Request		Terminal Disc	claimer		X Other Enclosure(s) (please Identify below):		
Express Abandonment Request		Request for Refund			Return Receipt Postcard		
X Supplemental Information Disclosure Statement	CD, Number of CD(s)						
Certified Copy of Priority Document(s)		Landscape Table on CD					
Reply to Missing Parts/ Incomplete Application	R	emarks					
Reply to Missing Parts under 37 CFR 1.52 or 1.53							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
	WILMER CUTLER PICKERING HALE AND DORR LLP						
ignature Wille Superko							
Printed name Colleen Superko	7						
May 1, 2006			F	Reg. No.	39,850		

Express Mail Label No. EV621477401US	Dated: May 1, 2006	

Docket No.: 0036119.00161US2/AM101281

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

M. Merle ELLOSO et al.

Confirmation No.:

2403

Application No.:

10/751543

Art Unit:

1617

Filed:

January 5, 2004

Examiner:

S. Kantamneni

Title:

USE OF ESTROGEN RECEPTOR ALPHA MODULATORS FOR THE

TREATMENT OF MULTIPLE SCLEROSIS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: May 1, 2006

Colleen Superko

Registration No.: 39,850 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile)

MAY 0 1 2006

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/751543-Conf. #2403	
11	NFORMATION	I DI	SCLOSURE	Filing Date	January 5, 2004	
S	STATEMENT BY APPLICANT			First Named Inventor	M. Merle ELLOSO	
				Art Unit	1617	
	(Use as many sheets as necessary)			Examiner Name	Kantamneni	
Sheet	1	of	1	Attomey Docket Number	0036119.00161US2/AM101281	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
				·		

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Initials*	No. <sup>1</sup>	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)		Applicant of Cited Document		T <sup>6</sup>			
	ВА	EP 0 240 131	10-07-1987	IMPERIAL INDUSTRIES PLC					
l	BB	EP 0 667 768	03-03-1999	NIPPON KAYAKU					
				KABUSHIKI KAISHA et al.					
	ВС	EP 0 792 640	09-03-1997	PFIZER INC					
	BD	EP 0 792 641	09-03-1997	PFIZER INC		П			
	BE	EP 0 792 642	09-03-1997	PFIZER INC					
	BF	EP 1 120 114	08-01-2001	PFIZER PRODUCTS INC					
	BG	WO 93/22685	11-11-1993	THE GOVERNMENT OF THE					
				UNITED STATES OF					
l	İ			AMERICA as represented by					
ŀ				the DEPARTMENT OF					
				HEALTH AND HUMAN					
<b> </b>				SERVICES					
	ВН	WO 94/09764	05-11-1994	NIPPON KAYAKU					
				KABUSHIKI KAISHA et al.					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nich of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	CA	BADGER et al., "Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis," Journal of Pharmacology and Experimental Therapeutics, (1999), pp. 1380-1386, Vol. 291, No. 3.				
	СВ	GRANIGER et al., "Tamoxifen: Teaching an Old Drug New Tricks?" Nature Medicine, (1996), pp. 381-385, Vol. 2, No. 4.				
	CC	MARKUS et al., "Tamoxifen inhibits disease expression in murine experimental autoimmune encephalomyelitis," Neurology, (2000), pp. A61, Vol. 54, No. 7.				
	CD	XP002372596, DATABASE WPI, Abstract, (1998)				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	1

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.